#USA #Pittsburgh #PANTHERx Rare #KYGEVVI™ #UCB Group

PANTHERx Rare Becomes Exclusive Provider of KYGEVVI™

In an exciting development for the world of rare diseases, PANTHERx® Rare has been selected by UCB as the exclusive specialty pharmacy for the distribution of KYGEVVI™ (doxecitine and doxribtimine) powder for oral solution. This collaboration aims to enhance accessibility with an innovative approach to the treatment and management of rare diseases.

PANTHERx is well-known as a leader and innovator in patient access and support services tailored for individuals dealing with personal rare disease challenges. Their proprietary RxARECARE® model is set to play a crucial role in supporting patients, caregivers, and prescribers through this partnership. The goal is to provide comprehensive, therapy-specific clinical expertise and individualized case management. This approach is designed to simplify the often-complicated experience that comes with navigating rare disease therapies.

Bansi Nagji, CEO of PANTHERx Rare Pharmacy, expressed pride in this partnership, emphasizing the importance of personalized care. “We are proud to partner with UCB to support access to KYGEVVI and deliver the hyper-personalized care for eligible patients,” he stated. “TK2d, a rare genetic mitochondrial disease, poses daily challenges for families, and we are motivated by their inspiring resilience.” By tailoring support through its experienced RxARECARE teams, PANTHERx aims to significantly lessen the burden on both patients and their families.

Understanding TK2d

Thymidine Kinase 2 Deficiency (TK2d) is a rare inherited genetic disorder affecting the body’s ability to produce and repair mitochondrial DNA (mtDNA). Low mtDNA levels can lead to serious health complications, categorized under mitochondrial depletion syndromes. Symptoms can include muscle weakness and respiratory failure. Although the exact prevalence of TK2d remains unclear, it is recognized as exceptionally rare.

In making KYGEVVI available, PANTHERx aims to bridge the gap between complex medical treatments and the patients who need them. The linkage between patients, prescribers, and pharmaceutical partners enhances communication and support, ensuring that everyone involved is on the same page.

PANTHERx has made a name for itself by building deep personal relationships with each patient it serves. These relationships act as a foundation for the exceptional care that has helped establish PANTHERx as the largest independent rare pharmacy in the United States since its inception in 2011. Founded in a garage in Pittsburgh, PA, PANTHERx has maintained a unique balance between the resources of a large corporation and the responsiveness of a smaller entity, valuing innovation and meticulous attention to detail.

The pharmacy holds licenses across all 50 states and has achieved dual accreditations in rare diseases from both the Accreditation Commission for Health Care (ACHC) and the Utilization Review Accreditation Commission (URAC). Moreover, PANTHERx has been recognized eight times with the esteemed MMIT Patient Choice Award for high patient satisfaction, even receiving honors in 2025.

For individuals interested in learning more about PANTHERx Rare’s services and their new role in supporting the distribution of KYGEVVI, further information is accessible via their official website at www.pantherxrare.com or through direct email inquiries. This partnership symbolizes a significant leap forward for patients grappling with rare diseases, offering them hope and better support in their healthcare journeys.

Contact Information: For media inquiries, reach out to Jennifer May, Senior Manager of Marketing Communications at PANTHERx Rare.